Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Shareholder Meeting (March 2025)
19 slides from Rhythm Biosciences's shareholder meeting presentation, Mar 31, 2025
Slide 1: Investor Presentation
Investor Presentation 31ST MARCH 2025
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Agenda
Agenda Goal of Session Agenda 1. A review of the Rhythm’s 1. Rhythm Biosciences – a company transforming cancer diagnostics purpose and business goals 2. Development of ColoSTAT®: Rhythm’s opportunity to enter a 2. Summary of Rhythm’s blockbuster market innovative ColoSTAT® program 3. Introduction t
Slide 4: About Rhythm Biosciences
About Rhythm Biosciences Rhythm Biosciences is Rhythm is a health innovator driven by the singular purpose of giving people the earliest possible chance to take control of their health. committed to saving lives through the evaluation of Developing novel risk assessment and screening solutions for s
Slide 5: Corporate overview
Corporate overview CORPORATE SNAPSHOT SHARE PRICE CHART - ASX:RHY ASX Code RHY 1.8 Share Price (28th March 2025) $0.08 1.6 1.4 Shares on Issue 283,597M 1.2 Unlisted Options 21M 1 0.8 Market Capitalisation $22.7M 0.6 0.4 Cash in Bank (31 Dec. 2024) $4.37M 0.2 Top 20 Shareholders 42% 0 25/05/2022 25/1
Slide 6: Detecting cancer earlier and maintaining wellness
Detecting cancer earlier and maintaining wellness The power of the combination of the Rhythm and Genetype capabilities and portfolio Y N E R U O J Risk Assessment Disease Screening MONITORING AND MINIMAL RESIDUAL T RISK ASSESSMENT DISEASE DETECTION Determination Non-invasive detection N E of risk pr
Slide 7: Recent Highlights
Recent Highlights ✓ Significant progress achieved in 2nd ✓ Receipt of $3.2m Research & Generation ColoSTAT® Multiplex Alpha Development Tax Incentive (RDTI) Kit with superior analytical results return; compared to the 1st Generation Kit; ✓ Completion of a placement for $3.5m ✓ Delivery of 2nd Genera
Slide 8: ColoSTAT Development
HA RHYTHM BIOSCIENCES ColoSTAT® Development
Slide 9: Faster turnaround time, lower cost, updated & simplified ColoSTAT Kit
Faster turnaround time, lower cost, updated & simplified ColoSTAT® Kit Multiplex Planar – Five Plates to a Single Plate Based ELISA (Five reagents to a single kit) Reduced Cost Materials, Packaging and Transport Updated Test Kit Reduced Chance of Human Error Embraces Increased Automation and Efficie
Slide 10: ColoSTAT 2025 Development Activities
ColoSTAT® 2025 Development Activities Key Activities Next Steps 1 Assay Kit Verification • Verification of kit analytical specification 2 Pilot Production • Finalise kit transfer to manufacturing • Assay performance evaluation with patient samples and development of a 3 Kit Analytical Validation Stu
Slide 11: Genetype Acquisition
HA RHYTHM BIOSCIENCES Genetype Acquisition
Slide 12: Genetype acquisition by Rhythm
Genetype acquisition by Rhythm Overview Acquisition Drivers • Expanding our product scope to risk assessment supports the mission of • Rhythm Biosciences early detection of cancer. completed the asset • Risk assessment and screening solutions are highly complimentary. acquisition agreement • The acq
Slide 13: About the geneType product
About the geneTypeTM product A leading genomic testing portfolio • The geneTypeTM product portfolio is a world-leading personalised • geneTypeTM clinical performance has been established and predictive test portfolio that uses a unique combination of published2 with two examples being: genomic and c
Slide 14: geneType opportunities for 2025
geneTypeTM opportunities for 2025 Oncology Portfolio Focus Customer Segments • Breast* • Ovarian • Health Care Professionals – B2B • Prostate • Melanoma • Strategic partners – B2B2B • Colorectal* • Pancreatic* * Rhythm protein biomarker program overlap. Geographical Priorities Commercial Channels •
Slide 15: Product Roadmap
HA RHYTHM BIOSCIENCES Product Roadmap
Slide 16: Our combined platforms supports a highly comprehensive approach to cancer diagnostics
Our combined platforms supports a highly comprehensive approach to cancer diagnostics The potential RHY product portfolio addresses a huge total available market Y N E R U O J T MONITORING AND RISK MINIMAL RESIDUAL N ASSESSMENT DISEASE DETECTION E Risk Assessment • • • • • • • • • I T P A Surveillan
Slide 17: 2025 Catalysts
HA RHYTHM BIOSCIENCES 2025 Catalysts
Slide 18: Upcoming value inflection points
Upcoming value inflection points PRODUCT ITEM DESCRIPTION ESTD. DELIVERY DATE ColoSTAT® Alpha Assay Ready Arrival of Alpha kits for testing ColoSTAT® Beta Release Candidate Beta Kits ready for verification geneTypeTM Genetype business integration Complete integration of Genetype organisation ColoSTA
Slide 19: Thank you!
Thank you! david.atkins@rhythmbio.com www.rhythmbio.com
Rhythm Biosciences — Shareholder Meeting (March 2025) on 6ix